search
Back to results

Role of Microvascular Insulin Resistance and Cardiorespiratory Fitness Diabetes (REACH)

Primary Purpose

Type 2 Diabetes, Overweight and Obesity

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Cardiovascular exercise
Sponsored by
University of Colorado, Denver
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes

Eligibility Criteria

30 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Sedentary (defined as less than 1 hour per week of physical activity)
  • BMI: 25-40
  • Men and women with and without type 2 diabetes

Exclusion Criteria:

  • Documented cardiovascular disease
  • Uncontrolled hypertension: disease systolic blood pressure (SBP) > 150, diastolic blood pressure (DBP)> 110
  • Obstructive pulmonary disease or asthma
  • Peripheral neuropathy
  • Physical impairment that would limit exercise ability
  • Subjects taking beta blockers, calcium channel blockers, insulin, or Thiazolidinediones (TZD)
  • Current or past smoking within the last 1 years
  • Current tobacco use
  • Anemia
  • Control HbA1c > 5.7, T2DM HbA1c > 9
  • Pregnant, nursing or hormonal therapy (other than contraceptives)
  • Peri or post-menopausal women
  • Type 1 diabetes
  • Hepatic or renal disease.

Sites / Locations

  • University of ColoradoRecruiting
  • University of VirginiaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Type 2 Diabetes

Healthy overweight control

Arm Description

Participants aged 30-55 with type 2 diabetes

Participants aged 30-55 with BMI 25-40 without type 2 diabetes

Outcomes

Primary Outcome Measures

Change in peak oxygen consumption (VO2)
Subjects' peak oxygen consumption will be tested on a stationary bike before and after 15 weeks of exercise
Change in insulin sensitivity
The investigators will evaluate the changes in insulin sensitivity utilizing a euglycemic insulin clamp

Secondary Outcome Measures

Full Information

First Posted
March 8, 2021
Last Updated
July 10, 2023
Sponsor
University of Colorado, Denver
Collaborators
University of Virginia, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
search

1. Study Identification

Unique Protocol Identification Number
NCT04791371
Brief Title
Role of Microvascular Insulin Resistance and Cardiorespiratory Fitness Diabetes
Acronym
REACH
Official Title
Role of Microvascular Insulin Resistance and Cardiorespiratory Fitness Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 17, 2022 (Actual)
Primary Completion Date
September 1, 2026 (Anticipated)
Study Completion Date
December 1, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Colorado, Denver
Collaborators
University of Virginia, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this two-site grant proposal is to determine the role of the decreased insulin-mediated muscle perfusion found in type 2 diabetes in contributing to the development of cardiac and skeletal muscle dysfunction and subsequent functional exercise impairment. In addition, it is also our goal to determine whether exercise training attenuates insulin resistance and restores insulin-mediated perfusion to the heart and to skeletal muscle, leading to improved cardiac function and exercise performance.
Detailed Description
It is our goal to determine whether exercise training attenuates insulin resistance and restores insulin-mediated perfusion to the heart and to skeletal muscle, leading to improved cardiac function and exercise performance. Data from our two research teams suggest that the cardiac and skeletal muscle microvascular dysfunction present in people with type 2 diabetes contributes to limitations in cardiac and skeletal muscle function associated with impaired functional exercise capacity (a major predictor of CV and all-cause mortality). Insulin action is a potent predictor of the functional exercise capacity impairment in type 2 diabetes. The exact relationship between insulin action, cardiac and muscle dysfunction, cardiac and skeletal muscle perfusion and decreased functional exercise capacity in type 2 diabetes remains unclear.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes, Overweight and Obesity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Type 2 Diabetes
Arm Type
Experimental
Arm Description
Participants aged 30-55 with type 2 diabetes
Arm Title
Healthy overweight control
Arm Type
Experimental
Arm Description
Participants aged 30-55 with BMI 25-40 without type 2 diabetes
Intervention Type
Behavioral
Intervention Name(s)
Cardiovascular exercise
Intervention Description
15 weeks of cardiovascular exercise 3x/week for 50 minutes/session
Primary Outcome Measure Information:
Title
Change in peak oxygen consumption (VO2)
Description
Subjects' peak oxygen consumption will be tested on a stationary bike before and after 15 weeks of exercise
Time Frame
Through study completion, approximately 4 months
Title
Change in insulin sensitivity
Description
The investigators will evaluate the changes in insulin sensitivity utilizing a euglycemic insulin clamp
Time Frame
Through study completion, approximately 4 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Sedentary (defined as less than 1 hour per week of physical activity) BMI: 25-40 Men and women with and without type 2 diabetes Exclusion Criteria: Documented cardiovascular disease Uncontrolled hypertension: disease systolic blood pressure (SBP) > 150, diastolic blood pressure (DBP)> 110 Obstructive pulmonary disease or asthma Peripheral neuropathy Physical impairment that would limit exercise ability Subjects taking beta blockers, calcium channel blockers, insulin, or Thiazolidinediones (TZD) Current or past smoking within the last 1 years Current tobacco use Anemia Control HbA1c > 5.7, T2DM HbA1c > 9 Pregnant, nursing or hormonal therapy (other than contraceptives) Peri or post-menopausal women Type 1 diabetes Hepatic or renal disease.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Benjamin Juckett, MS
Phone
303-724-1338
Email
benjamin.juckett@cuanschutz.edu
Facility Information:
Facility Name
University of Colorado
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Benjamin Juckett, MS
Phone
303-724-1338
Email
benjamin.juckett@cuanschutz.edu
First Name & Middle Initial & Last Name & Degree
Ethan Clark, MS
Phone
303-724-1354
Email
ethan.w.clark@cuanschutz.edu
First Name & Middle Initial & Last Name & Degree
Judy Regensteiner, PhD
First Name & Middle Initial & Last Name & Degree
Jane Reusch, MD
Facility Name
University of Virginia
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22908
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lee Hartline, MEd
Phone
434-924-5247
Email
lmh9d@virginia.edu
First Name & Middle Initial & Last Name & Degree
Linda Jahn, RN
Phone
434-924-1134
Email
las6e@virginia.edu
First Name & Middle Initial & Last Name & Degree
Zhenqi Liu, MD

12. IPD Sharing Statement

Learn more about this trial

Role of Microvascular Insulin Resistance and Cardiorespiratory Fitness Diabetes

We'll reach out to this number within 24 hrs